The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Independent and Incremental Value of Deformation Indices for Prediction of Trastuzumab-Induced Cardiotoxicity
Open accessAbstract
BACKGROUND Assessment of left ventricular systolic function is necessary during trastuzumab-based chemotherapy because of potential cardiotoxicity. Deformation indices have been proposed as an adjunct to clinical risk factors and ejection fraction (EF), but the optimal parameter and optimal cutoffs are undefined. The aim of this study was to determine the best means of early detection of subsequent reduction of EF in patients with breast cancer treated with trastuzumab. METHODS Eighty-one consecutive women (mean age, 50 ± 11 years) receiving trastuzumab were prospectively studied, 37 of whom received concurrent anthracyclines. Conventional echocardiographic indices (mitral annular systolic [s'] and diastolic [e'] velocities) and myocardial deformation indices (global longitudinal peak systolic strain [GLS], global longitudinal peak systolic strain rate [GLSR-S], and global longitudinal early diastolic strain rate [GLSR-E]) were measured at baseline and at 6 and 12 months. Cardiotoxicity was defined as a >10% decline as a percentage of baseline EF in 12 months. RESULTS In the 24 patients (30%) who later developed cardiotoxicity, myocardial deformation indices decreased at 6 months (GLS, P < .001; GLSR-S, P = .009; GLSR-E, P = .002 vs baseline), but e' was unchanged. The strongest predictor of cardiotoxicity was ΔGLS (area under the curve, 0.84); an 11% reduction (95% confidence interval, 8.3%-14.6%) was the optimal cutoff, with sensitivity of 65% and specificity of 94%. In sequential models, the clinical model (χ(2) = 10.2) was improved by GLSR-S (χ(2) = 14.7, P = .03) and even more so by GLSR-E (χ(2) = 18.0, P = .005) or GLS (χ(2) = 21.3, P = .0008). Discrimination improvement by adding GLS was confirmed by an integrated discrimination improvement of 18.6% (95% confidence interval, 8.6%-28.6%; P = .0003). A net 29% of the patients without events were reclassified into lower risk categories, and a net 48% of the patients with events were reclassified into higher risk categories, resulting in a total continuous net reclassification improvement (>0) of 0.77 (95% confidence interval, 0.33-1.22; P = .036). CONCLUSIONS GLS is an independent early predictor of later reductions in EF, incremental to usual predictors in patients at risk for trastuzumab-induced cardiotoxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
Jemal, A., Siegel, R., Xu, J., & Ward, E. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20073 · Cited by 12,596
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Lang, R. M., Bierig, M., Devereux, R. B., Flachskampf, F. A., Foster, E., Pellikka, P. A., Picard, M. H., Roman, M. J., Seward, J., Shanewise, J. S., et al. (2005) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2005.10.005 · Cited by 11,318
Pencina, M. J., D' Agostino, R. B., D' Agostino, R. B., & Vasan, R. S. (2008) · Statistics in Medicine · doi:10.1002/sim.2929 · Cited by 6,493
Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Davidson, N. E., Tan-Chiu, E., Martino, S., Paik, S., Kaufman, P. A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052122 · Cited by 5,356
Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., Gianni, L., Baselga, J., Bell, R., Jackisch, C., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052306 · Cited by 5,084
Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers
Pencina, M. J., D'Agostino, R. B., & Steyerberg, E. W. (2011) · Statistics in Medicine · doi:10.1002/sim.4085 · Cited by 2,453
Underlying Causes and Long-Term Survival in Patients with Initially Unexplained Cardiomyopathy
Felker, G. M., Thompson, R. E., Hare, J. M., Hruban, R. H., Clemetson, D. E., Howard, D. L., Baughman, K. L., & Kasper, E. K. (2000) · New England Journal of Medicine · doi:10.1056/nejm200004133421502 · Cited by 1,723
Self-citationCardiac Dysfunction in the Trastuzumab Clinical Trials Experience
Seidman, A. D., Hudis, C. A., Pierri, M. K., Shak, S., Paton, V. E., Ashby, M. A., Murphy, M., Stewart, S. J., & Keefe, D. L. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.5.1215 · Cited by 1,563
Greenland, P. (2008) · Statistics in Medicine · doi:10.1002/sim.2976 · Cited by 1,300
Mor-Avi, V., Lang, R. M., Badano, L. P., Belohlavek, M., Cardim, N. M., Derumeaux, G., Galderisi, M., Marwick, T., Nagueh, S. F., Sengupta, P. P., et al. (2011) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2011.01.015 · Cited by 1,254
Self-citationLamon, D. E. J. S., Eyland, B. R. L., Hak, S. T. S., Uchs, H. A. F., Aton, V. I. P., Ajamonde, A. L. B., LeMing, T., Iermann, W. O. E., Olter, J. A. W., Egram, M. A. P., et al. (2009) · Cited by 1,199
Leitman, M., Lysyansky, P., Sidenko, S., Shir, V., Peleg, E., Binenbaum, M., Kaluski, E., Krakover, R., & Vered, Z. (2004) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2004.06.019 · Cited by 1,187
Sawaya, H., Sebag, I. A., Plana, J. C., Januzzi, J. L., Ky, B., Tan, T. C., Cohen, V., Banchs, J., Carver, J. R., Wiegers, S. E., et al. (2012) · Circulation: Cardiovascular Imaging · doi:10.1161/circimaging.112.973321 · Cited by 814
Self-citationEarly Detection and Prediction of Cardiotoxicity in Chemotherapy-Treated Patients
Sawaya, H., Sebag, I. A., Plana, J. C., Januzzi, J. L., Ky, B., Cohen, V., Gosavi, S., Carver, J. R., Wiegers, S. E., Martin, R. P., et al. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2011.01.006 · Cited by 682
Self-citationTrastuzumab-Induced Cardiotoxicity: Clinical and Prognostic Implications of Troponin I Evaluation
Cardinale, D., Colombo, A., Torrisi, R., Sandri, M. T., Civelli, M., Salvatici, M., Lamantia, G., Colombo, N., Cortinovis, S., Dessanai, M. A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.3615 · Cited by 641
Fallah-Rad, N., Walker, J. R., Wassef, A., Lytwyn, M., Bohonis, S., Fang, T., Tian, G., Kirkpatrick, I. D. C., Singal, P. K., Krahn, M., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.11.063 · Cited by 484
Eschenhagen, T., Force, T., Ewer, M. S., de Keulenaer, G. W., Suter, T. M., Anker, S. D., Avkiran, M., de Azambuja, E., Balligand, J.-L., Brutsaert, D. L., et al. (2011) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfq213 · Cited by 413
Otterstad, J. E., Froeland, G., St. John Sutton, M., & Holme, I. (1997) · European Heart Journal · doi:10.1093/oxfordjournals.eurheartj.a015273 · Cited by 394
Trastuzumab‐associated cardiotoxicity
Keefe, D. L. (2002) · Cancer · doi:10.1002/cncr.10854 · Cited by 358
Ho, E., Brown, A., Barrett, P., Morgan, R. B., King, G., Kennedy, M. J., & Murphy, R. T. (2010) · Heart · doi:10.1136/hrt.2009.173997 · Cited by 242
Hare, J. L., Brown, J. K., Leano, R., Jenkins, C., Woodward, N., & Marwick, T. H. (2009) · American Heart Journal · doi:10.1016/j.ahj.2009.05.031 · Cited by 230
Self-citationTASSANMANGINA, S., CODOREAN, D., METIVIER, M., COSTA, B., HIMBERLIN, C., JOUANNAUD, C., BLAISE, A., ELAERTS, J., & NAZEYROLLAS, P. (2006) · European Journal of Echocardiography · doi:10.1016/j.euje.2005.04.009 · Cited by 213
Left Ventricular Ejection Fraction and Cardiotoxicity: Is Our Ear Really to the Ground?
Ewer, M. S., & Lenihan, D. J. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8742 · Cited by 207
Bansal, M., Cho, G.-Y., Chan, J., Leano, R., Haluska, B. A., & Marwick, T. H. (2008) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2008.09.021 · Cited by 186
Self-citationTrastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors
Serrano, C., Cortés, J., De Mattos-Arruda, L., Bellet, M., Gómez, P., Saura, C., Pérez, J., Vidal, M., Muñoz-Couselo, E., Carreras, M. J., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mdr348 · Cited by 161
Mercuro, G., Dessalvi, C. C., Piras, A., Dessì, M., Madeddu, C., Deidda, M., Serpe, R., Massa, E., & Mantovani, G. (2007) · The Oncologist · doi:10.1634/theoncologist.12-9-1124 · Cited by 147
Mackey, J. R., Clemons, M. J., Côté, M. A., Delgado, D., Dent, S. F., Paterson, A., Provencher, L., Sawyer, M. B., & Verma, S. (2008) · Current Oncology · doi:10.3747/co.2008.199 · Cited by 142
Tjeerdsma, G., Meinardi, M. T., van der Graaf, W. T. A., van den Berg, M. P., Mulder, N. H., Crijns, H. J. G. M., de Vries, E. G. E., & van Veldhuisen, D. J. (1999) · Heart · doi:10.1136/hrt.81.4.419 · Cited by 115
Chen, M. H., Colan, S. D., & Diller, L. (2011) · Circulation Research · doi:10.1161/circresaha.110.224519 · Cited by 112
Cited by
Thavendiranathan, P., Poulin, F., Lim, K.-D., Plana, J. C., Woo, A., & Marwick, T. H. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.01.073 · Cited by 1,079
Self-citationCurigliano, G., Lenihan, D., Fradley, M., Ganatra, S., Barac, A., Blaes, A., Herrmann, J., Porter, C., Lyon, A. R., Lancellotti, P., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2019.10.023 · Cited by 1,031
Metadata
- Authors
- Negishi, K., Negishi, T., Hare, J. L., Haluska, B. A., Plana, J. C., & Marwick, T. H.
- Venue
- Journal of the American Society of Echocardiography
- Publisher
- Elsevier BV
- Published
- 2013-05
- Volume
- 26
- Issue
- 5
- Pages
- 493-498
- ISSN
- 0894-7317 (ISSN-L)
- OpenAlex
- W1968148627
- Cited by
- 454
- References
- 32
- FWCI
- 23.09
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.